HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Tenaya Therapeutics (NASDAQ:TNYA) and maintains an $18 price target.
March 19, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Tenaya Therapeutics with an $18 price target.
The reiteration of a Buy rating and maintenance of an $18 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors and potentially lead to a positive short-term impact on TNYA's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100